MedWatch

Novo’s R&D chief: Semaglutide wins out every time

Novo Nordisk's major pipeline hope semaglutide has bested pretty much every major diabetes drug on the market in head-to-head studies, says CSO Mads Krogsgaard Thomsen. But the group will still have to beat out two more products before the GLP-1 analogue can be seen as the king of the clinic.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Dansk biotekboss rejser 91 mio til at udfordre Novo Nordisk

Et amerikansk biotekselskab, som er grundlagt af en dansk molekylærbiolog, har rejst 91 mio. kr. til at fremme programmer inden for diabetes, fedme og fedtlever, herunder et "transformativt" diabeteslægemiddel rettet mod biologiske mål, som Novo Nordisk også arbejder med.

Related articles